This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Aimmune Set to be Acquired by Nestle for $2.6B, Stock Up
by Zacks Equity Research
Aimmune (AIMT) reaches an agreement with Nestle, S.A wherein the latter will acquire the company in an all-cash transaction worth $2.6 billion. Shares surge.
Company News for Sep1, 2020
by Zacks Equity Research
Companies In The News Are: CTLT, TSLA, AIMT, AMZN.
Aimmune Therapeutics (AIMT) Reports Q2 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aimmune Therapeutics (AIMT) delivered earnings and revenue surprises of 0.00% and -100.00%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Aimmune Therapeutics (AIMT) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
Aimmune Therapeutics (AIMT) delivered earnings and revenue surprises of 10.44% and -67.14%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Is the Options Market Predicting a Spike in Aimmune (AIMT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Aimmune (AIMT) stock based on the movements in the options market lately.
What's in Store for Aimmune (AIMT) This Earnings Season?
by Zacks Equity Research
Aimmune (AIMT) is likely to provide an update on Palforzia's launch plans during Q4 investors' call. The drug gets an approval in January 2020 for the treatment of peanut allergy.
Biotech Stock Roundup: Earnings Updates From VRTX, AMGN, GILD; AIMT Gains FDA Nod
by Zacks Equity Research
Many biotech bigwigs came out with their fourth-quarter numbers in the past week.
Aimmune's Palforzia Wins FDA Approval for Peanut Allergy
by Zacks Equity Research
Aimmune's (AIMT) Palforzia is the first medicine to receive an FDA nod for treating patients with peanut allergy. Shares rise in pre-market trading.
Is the Options Market Predicting a Spike in Aimmune Therapeutics (AIMT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Aimmune Therapeutics (AIMT) stock based on the movements in the options market lately.
Biotech Stock Roundup: BIIB Halts AD Study, AMGN Posts Positive MM Drug Data & More
by Zacks Equity Research
Key highlights of the past week include regulatory and pipeline updates, acquisition deals, and more.
Aimmune's Peanut Allergy Drug Gets FDA Committee's Support
by Zacks Equity Research
Aimmune's (AIMT) peanut allergy drug gets majority of votes from the Advisory Committee of the FDA.
Implied Volatility Surging for Aimmune (AIMT) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Aimmune (AIMT) stock based on the movements in the options market lately.
Aimmune Down on Negative ICER Review on Allergy Candidate
by Zacks Equity Research
Aimmune's (AIMT) peanut allergy candidate AR101 attracts negative review from ICER, stating risks outweighs benefits in patients. AR101 is under review and a decision is expected by January 2020.
What Makes Aimmune Therapeutics (AIMT) a New Buy Stock
by Zacks Equity Research
Aimmune Therapeutics (AIMT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus
by Zacks Equity Research
Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus
NASH, Allergies and Beauty Stocks: Invest or Not?
by Tracey Ryniec
There's a lot of innovation going on at the biopharmaceutical companies but which areas should investors be targeting?
Are Options Traders Betting on a Big Move in Aimmune Therapeutics (AIMT) Stock?
by Zacks Equity Research
Investors need to pay close attention to Aimmune Therapeutics (AIMT) stock based on the movements in the options market lately.
Roche's (RHHBY) Xolair Gets Breakthrough Therapy Status
by Zacks Equity Research
Genentech's, a subsidiary of Roche (RHHBY), allergy drug, Xolair, gets Breakthrough Therapy designation in the United States for the prevention of severe food allergic reactions.
Is a Beat in Store for Ionis (IONS) This Earnings Season?
by Zacks Equity Research
On Ionis' (IONS) second-quarter 2018 conference call, investor focus will remain on the company's progress with the pipeline candidates as well as royalty revenues earned from Spinraza.
Is a Beat in the Cards for Merrimack (MACK) in Q2 Earnings?
by Zacks Equity Research
On Merrimack's (MACK) second-quarter 2018 conference call, investor focus will be on the company's progress with pipeline candidates.
Company News For Mar 5, 2018
by Zacks Equity Research
Companies In The News are: JCP,AIMT,QCP,GPS
Is the Options Market Predicting a Spike in Aimmune Therapeutics (AIMT) Stock?
by Zacks Equity Research
Investors in Aimmune Therapeutics (AIMT) need to pay close attention to the stock based on moves in the options market lately.
Aimmune Therapeutics (AIMT) in Focus: Stock Moves 6.3% Higher
by Zacks Equity Research
Aimmune Therapeutics (AIMT) shares rose more than 6% in the last trading session, amid huge volumes.
AVEO Pharmaceuticals (AVEO) Worth a Look: Stock Up 14.8%
by Zacks Equity Research
AVEO Pharmaceuticals, Inc. (AVEO) shares rose around 15% in the last trading session.
Aimmune Therapeutics (AIMT) Shares March Higher, Can It Continue?
by Zacks Equity Research
As of late, it has definitely been a great time to be an investor in Aimmune Therapeutics Inc (AIMT).